Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vadadustat once-daily for anemia of chronic kidney disease in pediatric, ESA-naive subjects
2021-003994-72Phase 3Terminated
- Sponsor
- Akebia Therapeutics
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vadadustat in anemia of chronic kidney disease, sponsored by Akebia Therapeutics. Primary endpoint: Primary efficacy endpoint: change in hemoglobin. Started Dec 2021; status: terminated.
02
Drugs
vadadustat
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on 2021-003994-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003994-72.